Integrated frontiers in mucosal defense: Evaluating next-generation vaccination strategies against Shigella infection

Vivek Kumar Dhiman,  Devendra Singh,  Manju Kumari   

Open Access   

Published:  Nov 20, 2026

DOI: 10.7324/jabb.2027.306011
Abstract

Shigella invades the colonic epithelium through mucosal surfaces, where low infectious doses enable rapid intracellular spread and severe inflammatory damage before systemic immunity becomes effective. Consequently, effective vaccination requires localized mucosal immune responses capable of preventing epithelial adhesion, invasion, and bacterial dissemination. Current mucosal vaccine strategies target the induction of secretory IgA (SIgA), which mediates immune exclusion by neutralizing bacteria within the mucus layer and limiting epithelial attachment. Simultaneously, mucosal vaccination promotes the formation of CD69+CD103+ tissue-resident memory T cells that provide rapid local recall responses independent of circulating lymphocytes. Recent evidence also demonstrates that Shigella exposure induces trained innate immunity through pattern recognition receptor (PRR)-mediated epigenetic and metabolic reprogramming, including H3K4me3-associated chromatin remodeling, enhanced glycolysis, and amplified IL-1β signaling, resulting in increased phagocytic and bactericidal activity. To induce these coordinated responses, next-generation vaccine platforms increasingly employ GMMA-based formulations, InvaplexAR-Detox systems, bacterial endotoxin conditioning center -engineered live-attenuated strains, double-mutant heat-labile toxin adjuvants, PRR agonists, and nanoparticle-mediated mucosal delivery systems. Oral and intranasal administration remain the most effective routes for inducing integrated mucosal immunity, including SIgA production, tissue-resident memory T-cell establishment, and innate immune imprinting. Together, these advances support the development of mechanistically integrated mucosal vaccines capable of providing durable protection against shigellosis.


Keywords:     Shigella mucosal vaccine secretory IgA tissue-resident memory T cells trained immunity


Citation:

Dhiman VK, Singh D, Kumari M. Integrated frontiers in mucosal defense: Evaluating next-generation vaccination strategies against Shigella infection. J Appl Biol Biotech 2027. Article in Press. http://doi.org/10.7324/jabb.2027.306011

Copyright: Author(s). This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike license.

HTML Full Text
Reference

1. Singh D, Singh V, Bhushan Mishra S, Sharma D, Agarwal V. Evaluation of anti-biofilm, anti-quorum, anti-dysenteric potential of designed polyherbal formulation: in vitro and in vivo study. J Appl Biomed 2022;20(7):7–14; doi: https://doi.org/10.32725/jab.2022.005

2. Singh D, Sharma D, Agarwal V. Screening of anti-microbial, anti-biofilm activity, and cytotoxicity analysis of a designed polyherbal formulation against shigellosis. J Ayurveda Integr Med 2021;12:601– 6; doi: https://doi.org/10.1016/j.jaim.2021.06.007

3. Guzman CA, Borsutzky S, Favre D, Dietrich G. Vaccines against Infections Caused by Salmonella, Shigella, and Pathogenic Escherichia coli. EcoSal Plus 2004;1(1): doi: https://doi.org/10.1128/ecosalplus.8.8.14

4. MacLennan CA, Grow S, Ma LF, Steele AD. The Shigella vaccines pipeline. Vaccines (Basel) 2022;10(9):1376; doi: https://doi.org/10.3390/vaccines10091376

5. Corthésy B, Spertini F. Secretory immunoglobulin A: from mucosal protection to vaccine development. Biol Chem 1999;380:1251–62; doi: https://doi.org/10.1515/BC.1999.160

6. Hassert M, Harty JT. Tissue resident memory T cells-A new benchmark for the induction of vaccine-induced mucosal immunity. Front Immunol 2022;13:1039194; doi: https://doi.org/10.3389/fimmu.2022.1039194

7. Correa VA, Portilho AI, De Gaspari E. Vaccines, adjuvants and key factors for mucosal immune response. Immunology 2022;167(2):124-38; doi: https://doi.org/10.1111/imm.13526

8. Clements JD, Norton EB. The mucosal vaccine adjuvant LT(R192G/L211A) or dmLT. mSphere 2018;3(4):e00215-18. doi: https://doi.org/10.1128/mSphere.00215-18

9. Turbyfill KR, Clarkson KA, Vortherms AR, Oaks EV, Kaminski RW. Assembly, biochemical characterization, immunogenicity, adjuvanticity, and efficacy of Shigella artificial invaplex. mSphere 2018;3(2):e00583; doi: https://doi.org/10.1128/mSphere.00583-17

10. Kaminski RW, Turbyfill KR, Oaks EV. Mucosal adjuvant properties of the Shigella invasin complex. Infect Immun 2006;74(5):2856–66; doi: https://doi.org/10.1128/IAI.74.5.2856-2866.2006

11. Zhou X, Wu Y, Zhu Z, Lu C, Zhang C, Zeng L, et al. Mucosal immune response in biology, disease prevention and treatment. Signal Transduct Target Ther 2025;10(7):7; doi: https://doi.org/10.1038/s41392-024-02043-4

12. Gomes MC, Brokatzky D, Mostowy S. Shigella-trained pro-inflammatory macrophages protect zebrafish from secondary infection. Cell Rep 2025;44(5):115601; doi: https://doi.org/10.1016/j.celrep.2025.115601

13. Wang S, Liang B, Wang W, Li L, Feng N, Zhao Y, et al. Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases. Signal Transduct Target Ther 2023;8(1):149; doi: 10.1038/s41392-023-01408-5

14. Lavelle EC, Ward RW. Mucosal vaccines—fortifying the frontiers. Nature Rev Immunol 2022;22:236–50; doi: https://doi.org/10.1038/s41577-021-00583-2

15. Brunner K, Samassa F, Sansonetti PJ, Phalipon A. Shigella-mediated immunosuppression in the human gut: subversion extends from innate to adaptive immune responses. Hum Vaccin Immunother 2019;15:1317–25; doi: https://doi.org/10.1080/21645515.2019.1594 132

16. Lee WH, Kim E. Mucosal vaccine development: from adjuvant design to next-generation delivery strategies. Biomedicines 2026;14:1060; doi: https://doi.org/10.3390/biomedicines14051060

17. Camacho F. Seal The Entry, Win The War: mucosal Vaccines For A Safer Tomorrow. BioNatura J Ibero-American J Biotechnol Life Sci 2025;2(12):12; doi: https://doi.org/10.70099/BJ/2025.02.02.12

18. Gao Y, Guo Y. Research progress in the development of natural-product-based mucosal vaccine adjuvants. Front Immunol 2023;14:1152855doi: https://doi.org/10.3389/fimmu.2023.1152855

19. Taebnia N, Römling U, Lauschke VM. In vitro and ex vivo modeling of enteric bacterial infections. Gut Microbes 2023;15(1):2158034; doi: https://doi.org/10.1080/19490976.2022.2158034

20. Ashida H, Mimuro H, Sasakawa C. Shigella manipulates host immune responses by delivering effector proteins with specific roles. Front Immunol 2015;6:219; doi: https://doi.org/10.3389/fimmu.2015.00219

21. Leroux-Roels I, Maes C, Mancini F, Jacobs B, Sarakinou E, Alhatemi A, et al. Safety and Immunogenicity of a 4-component generalized modules for membrane antigens Shigella vaccine in healthy European adults: randomized, Phase ½ Study. J Infect Dis 2024;230:e971–84; doi: https://doi.org/10.1093/infdis/jiae273

22. GSK licenses Shigella vaccine candidate to Bharat Biotech for continued development. 2025. Available at: https://www.gsk.com/en-gb/media/press-releases/gsk-licenses-shigella-vaccine-candidate-to-bharat-biotech-for-continued-development/(Accessed: 5 September 2026).

23. Conti V, Rossi O, Clarkson KA, Mancini F, Nakakana UN, Sarakinou E, et al. Putative correlates of protection against shigellosis assessing immunomarkers across responses to S. sonnei investigational vaccine. NPJ Vaccines 2024;9:56; doi: https://doi.org/10.1038/s41541-024-00822-2

24. Ledov V, Romanenko V, Golovina M, Alkhazova B, Kovalchuk A, Aparin P. A Candidate Ac3-S-LPS Vaccine Against S. flexneri 1b, 2a, 3a, 6, and Y Activates Long-Lived Systemic and Mucosal Immune Responses in Healthy Volunteers: results of an Open-Label, Randomized Phase 2 Clinical Trial. Vaccines 2025;13:209; doi: https://doi.org/10.3390/vaccines13030209

25. Parvej MS, Lu T, Maiti S, Dietz ZK, Howlader DR, Zahan MN, et al. The fusion subunit vaccine L-DBF protects aged mice against heterologous lethal Shigella challenge after prior exposure. Front Immunol 2025;16:1586537; doi: https://doi.org/10.3389/fimmu.2025.1586537

26. Terrinoni M, Holmgren J, Turbyfill KR, Van De Verg L, Maier N, et al. Potential for a combined oral inactivated whole-cell vaccine against ETEC and Shigella: preclinical studies supporting feasibility. Vaccines (Basel) 2025;13:513; doi: https://doi.org/10.3390/vaccines13050513

27. Janardhanan J, Wagh C, Yang J, Charles RC, Pansuriya RK, Chowdhury F, et al. An O-Specific Polysaccharide Shigella flexneri 3a Conjugate Vaccine is Immunogenic and Protective against Virulent Keratoconjunctival Challenge in Guinea Pigs. Am J Trop Med Hyg 2025;113:737–43; doi: https://doi.org/10.4269/ajtmh.25-0269

28. Vansofla AN, Hajizade A, Nazarian S, Tarverdizadeh Y, Shahmaleki A. An in-silico-designed multiepitope vaccine candidate can efficiently protect mice against pathogenic species of Shigella. J Immunol Methods 2025;542:113905; doi: https://doi.org/10.1016/j.jim.2025.113905

29. Talaat KR, Alaimo C, Martin P, Bourgeois AL, Dreyer AM, Kaminski RW, et al. Human challenge study with a Shigella bioconjugate vaccine: analyses of clinical efficacy and correlate of protection. EBioMedicine 2021;66:103310; doi: https://doi.org/10.1016/j.ebiom.2021.103310

30. Micoli F, Nakakana UN, Berlanda Scorza F. Towards a Four-Component GMMA-Based Vaccine against Shigella. Vaccines 2022;10:328; doi: https://doi.org/10.3390/vaccines10020328

31. Riddle MS, Kaminski RW, Di Paolo C, Porter CK, Gutierrez RL, Clarkson KA, et al. Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I Study. Clin Vaccine Immunol 2016;23:908–17; doi: https://doi.org/10.1128/CVI.00224-16

32. Li S, Han X, Upadhyay I, Zhang W. Characterization of Functional B-Cell Epitopes at the Amino Terminus of Shigella Invasion Plasmid Antigen B (IpaB). Appl Environ Microbiol 2022;88(15):e00384–22; doi: https://doi.org/10.1128/aem.00384-22

33. Haldar R, Halder P, Koley H, Miyoshi SI, Das S. A newly developed oral infection mouse model of shigellosis for immunogenicity and protective efficacy studies of a candidate vaccine. Infect Immun 2025;93(1):e00346–24; doi: https://doi.org/10.1128/iai.00346-24

34. Desalegn G, Abrahamson C, Ross Turbyfill K, Pill-Pepe L, Bautista L, Tamilselvi CS, et al. A broad spectrum Shigella vaccine based on VirG(53)(-)(353) multiepitope region produced in a cell-free system. NPJ Vaccines 2025;10(6):6; doi: https://doi.org/10.1038/s41541-025-01064-6

35. Sherman ME, Michalski J, Das S, Yang H, Chandrasekaran L, O’Meara TR, et al. BECC-engineered live-attenuated Shigella vaccine candidates display reduced endotoxicity with robust immunogenicity in mice. Vaccine 2025;50:126779; doi: https://doi.org/10.1016/j.vaccine.2025.126779

36. Roozen GVT, Sukwa N, Chirwa M, White J, et al. Safety, Tolerability, and Immunogenicity of the Invaplex(AR-Detox)Shigella Vaccine Co-Administered with the dmLT Adjuvant in Dutch and Zambian Adults: study Protocol for a Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase Ia/b Clinical Trial. Vaccines (Basel) 2025;13:48; doi: https://doi.org/10.3390/vaccines13010048

37. Brandtzaeg P. Secretory IgA: designed for Anti-Microbial Defense. Front Immunol 2013;4:222; doi: https://doi.org/10.3389/fimmu.2013.00222

38. Yadav P, Singh A, Kumari M, Verma SK, Singh D. Clinical evidence on BCG vaccination and COVID-19 infection: a systematic review. Respir Investig 2026;64:101422; doi: https://doi.org/10.1016/j.resinv.2026.101422

39. Pietrzak B, Tomela K, Olejnik-Schmidt A, Mackiewicz A, Schmidt M. Secretory IgA in Intestinal Mucosal Secretions as an Adaptive Barrier against Microbial Cells. Int J Mol Sci 2020;21:9254; doi: https://doi.org/10.3390/ijms21239254

40. Corthésy B. Role of secretory IgA in infection and maintenance of homeostasis. Autoimmun Rev 2013;12:661–5; doi: https://doi.org/10.1016/j.autrev.2012.10.012

41. Mathias A, Pais B, Favre L, Benyacoub J, Corthésy B. Role of secretory IgA in the mucosal sensing of commensal bacteria. Gut Microbes 2014;5(6):688–95; doi: https://doi.org/10.4161/19490976.2014.983763

42. Nizard M, Diniz MO, Roussel H, Tran T, Ferreira LC, Badoual C, et al. Mucosal vaccines: novel strategies and applications for the control of pathogens and tumors at mucosal sites. Hum Vaccin Immunother 2014;10:2175–87; doi: https://doi.org/10.4161/hv.29269

43. Li J, Wu G, Huang Z, Hu J, Tie X, Wu H, et al. Advances and prospects of respiratory mucosal vaccines: mechanisms, technologies, and clinical applications. NPJ Vaccines 2025;10(230):230; doi: https://doi.org/10.1038/s41541-025-01280-0

44. Correa VA, Portilho AI, De Gaspari E. Vaccines, adjuvants and key factors for mucosal immune response. Immunology 2022;167(2):124-38; doi: https://doi.org/10.1111/imm.13526

45. Akhtar M, Nizam NN, Basher SR, Hossain L, Akter S, Bhuiyan TR, et al. DmLT Adjuvant Enhances Cytokine Responses to T Cell Stimuli, Whole Cell Vaccine Antigens and Lipopolysaccharide in Both Adults and Infants. Front Immunol 2021;12:654872; doi: https://doi.org/10.3389/fimmu.2021.654872

46. Leach S, Clements JD, Kaim J, Lundgren A. The adjuvant double mutant Escherichia coli heat labile toxin enhances IL-17A production in human T cells specific for bacterial vaccine antigens. PLoS One. 2012;7(12):e51718; doi: https://doi.org/10.1371/journal.pone.0051718

47. Zhang Z, Hong W, Zhang Y, Li X, Que H, Wei X. Mucosal immunity and vaccination strategies: current insights and future perspectives. Mol Biomed 2025;6(57):57; doi: https://doi.org/10.1186/s43556-025-00301-7

48. Renu S, Renukaradhya GJ.Chitosan Nanoparticle Based Mucosal Vaccines Delivered Against Infectious Diseases of Poultry and Pigs. Front Bioeng Biotechnol 2020;8:558349; doi: https://doi.org/10.3389/fbioe.2020.558349

49. Desai DN, Mahal A, Varshney R, Obaidullah AJ, Gupta B, Mohanty P, et al. Nanoadjuvants: promising Bioinspired and Biomimetic Approaches in Vaccine Innovation. ACS Omega 2023;8:27953–68; doi: https://doi.org/10.1021/acsomega.3c02030

50. Schenkel JM, Masopust D. Tissue-resident memory T cells. Immunity 2014;41:886–97; doi: https://doi.org/10.1016/j.immuni.2014.12.007

51. Lyu Y, Zhou Y, Shen J.An Overview of Tissue-Resident Memory T Cells in the Intestine: from Physiological Functions to Pathological Mechanisms. Front Immunol 2022;13:912393; doi: https://doi.org/10.3389/fimmu.2022.912393

52. Park CO, Kupper TS. The emerging role of resident memory T cells in protective immunity and inflammatory disease. Nat Med 2015;21:688–97; doi: https://doi.org/10.1038/nm.3883

53. Lu T, Das S, Howlader DR, Jain A, Hu G, Dietz ZK, et al. Impact of the TLR4 agonist BECC438 on a novel vaccine formulation against Shigella spp. Front Immunol 2023;14:1194912; doi: https://doi.org/10.3389/fimmu.2023.1194912

54. Agren LC, Ekman L, Lowenadler B, Nedrud JG, et al. Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity. J Immunol 1999;162:2432–40; doi: https://doi.org/10.4049/jimmunol.162.4.2432

55. Liang H, Poncet D, Seydoux E, Rintala ND, Maciel M, Ruiz S, et al. The TLR4 agonist adjuvant SLA-SE promotes functional mucosal antibodies against a parenterally delivered ETEC vaccine. NPJ Vaccines 2019;4:19; doi: https://doi.org/10.1038/s41541-019-0116-6

56. Škrnjug I, Rueckert C, Libanova R, Lienenklaus S, Weiss S, Guzmán CA. The mucosal adjuvant cyclic di-AMP exerts immune stimulatory effects on dendritic cells and macrophages. PLoS One 2014;9(4):e95728; doi: https://doi.org/10.1371/journal.pone.0095728

57. Temizoz B, Ishii KJ.STING agonists as next-generation vaccine adjuvants: mechanisms, opportunities, and challenges. Curr Opin Virol 2026;30(76):101543; doi: https://doi.org/10.1016/j.coviro.2026.101543

58. Allen AC, Wilk MM, Misiak A, Borkner L, Murphy D, Mills KHG. Sustained protective immunity against Bordetella pertussis nasal colonization by intranasal immunization with a vaccine-adjuvant combination that induces IL-17-secreting T(RM) cells. Mucosal Immunol 2018;11:1763–76; doi: https://doi.org/10.1038/s41385-018-0080-x

59. Gomes MC, Brokatzky D, Bielecka MK, Wardle FC, Mostowy S. Shigella induces epigenetic reprogramming of zebrafish neutrophils. Sci Adv 2023;9:9706; doi: https://doi.org/10.1126/sciadv.adf9706

60. Pascual, D.W. Mucosal vaccines: innovation for preventing infectious diseases; Academic Press: 2019.

61. Boero E, Di Benedetto R, Vezzani G, Alfini R, Ceyssens PJ, Tansarli GS, et al. Antibodies elicited by altSonflex1-2-3 GMMA vaccine are bactericidal against a panel of drug-resistant Shigella clinical isolates. Front Immunol 2025;16:1652460; doi: https://doi.org/10.3389/fimmu.2025.1652460

62. Raso MM, Arato V, Gasperini G, Micoli F. Toward a Shigella Vaccine: opportunities and Challenges to Fight an Antimicrobial-Resistant Pathogen. Int J Mol Sci 2023;24; doi: https://doi.org/10.3390/ijms24054649

63. National Institute of Allergy and Infectious Diseases. Phase 2 Shigella Vaccine and Challenge; ClinicalTrials.gov: Bethesda, MD, 2025; ClinicalTrials.gov Identifier: NCT04242264. Available via https://clinicaltrials.gov/study/NCT04242264 (Accessed on 5 September 2026).

64. Kotloff KL, Simon JK, Pasetti MF, Sztein MB, Wooden SL, Livio S, et al. Safety and immunogenicity of CVD 1208S, a live, oral DeltaguaBA Deltasen Deltaset Shigella flexneri 2a vaccine grown on animal-free media. Hum Vaccin 2007;3(6):268–75; doi: https://doi.org/10.4161/hv.4746

65. Martin P, Alaimo C. The ongoing journey of a Shigella bioconjugate vaccine. Vaccines 2022;10:212; doi: https://doi.org/10.3390/vaccines10020212

66. Guo S, Puri R, Seth H, Chowdhury N, Chellappan G, Seal F, et al. Development of a Novel Shigella Quadrivalent Conjugate Vaccine Using Shigella O-Polysaccharide and IpaB Carrier Protein. Vaccines 2026;14:134; doi: https://doi.org/10.3390/vaccines14020134

67. Ashida H, Ogawa M, Mimuro H, Kobayashi T, Sanada T, Sasakawa C. Shigella are versatile mucosal pathogens that circumvent the host innate immune system. Curr Opin Immunol 2011;23(4):448–55; doi: https://doi.org/10.1016/j.coi.2011.06.001

68. Janovska S, Sleha R, Slovakova M, Pudelka L, Bostik P. Chitosan nanoparticles as delivery system for nasal immunisation. Mil Med Sci Letters/Vojenské Zdravotnické Listy 2023;92; doi: https://doi.org/10.31482/mmsl.2022.023

69. Girardin SE, Tournebize R, Mavris M, Page AL, Li X, Stark GR, et al. CARD4/Nod1 mediates NF-kappaB and JNK activation by invasive Shigella flexneri. EMBO Rep 2001;2(8):736–42; doi: https://doi.org/10.1093/embo-reports/kve155

70. Martin TL, Jee J, Kim E, Steiner HE, Cormet-Boyaka E, Boyaka PN. Sublingual targeting of STING with 3′3′-cGAMP promotes systemic and mucosal immunity against anthrax toxins. Vaccine 2017;35(18):2511–9; doi: https://doi.org/10.1016/j.vaccine.2017.02.064

71. Wei Q, Liu S, Huang X, Xin H, Ding J.Immunologically effective biomaterials-enhanced vaccines against infection of pathogenic microorganisms. Biosafety Health 2023;5:45–61; doi: https://doi.org/10.1016/j.bsheal.2022.11.002

72. Baruah N, Ahamad N, Halder P, Koley H, Katti DS. Facile synthesis of multi-faceted, biomimetic and cross-protective nanoparticle-based vaccines for drug-resistant Shigella: a flexible platform technology. J Nanobiotechnol 2023;21(34):34; doi: https://doi.org/10.1186/s12951-023-01780-y

73. Hashemi P, Osanloo M, Farjadfar A, Nasiri-Ghiri M, Zarenezhad E, Mahmoodi S. A multi-epitope protein vaccine encapsulated in alginate nanoparticles as a candidate vaccine against Shigella sonnei. Scientific Rep 2024;14:22484; doi: https://doi.org/10.1038/s41598-024-73105-4

74. An X, Martinez-Paniagua M, Rezvan A, Sefat SR, Fathi M, Singh S, et al. Single-dose intranasal vaccination elicits systemic and mucosal immunity against SARS-CoV-2. iScience 2021;24:103037; doi: https://doi.org/10.1016/j.isci.2021.103037

75. Camacho AI, Irache JM, De Souza J, Sánchez-Gómez S, Gamazo C. Nanoparticle-based vaccine for mucosal protection against Shigella flexneri in mice. Vaccine 2013;31(32):3288–94; doi: https://doi.org/10.1016/j.vaccine.2013.05.020

76. Drexler I, Staib C, Sutter G. Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential?. Curr Opin Biotechnol 2004;15:506–12; doi: https://doi.org/10.1016/j.copbio.2004.09.001

77. Levine MM, Kotloff KL, Barry EM, Pasetti MF, Sztein MB. Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road. Nat Rev Microbiol 2007;5(7):540–3; doi: https://doi.org/10.1038/nrmicro1662

78. Paciello I, Silipo A, Lembo-Fazio L, Curcurù L, Zumsteg A, Noël G, et al. Intracellular Shigella remodels its LPS to dampen the innate immune recognition and evade inflammasome activation. Proc Natl Acad Sci U S A 2013;110:E4345–4354; doi: https://doi.org/10.1073/pnas.1303641110

79. Arbibe L, Kim DW, Batsche E, Pedron T, Mateescu B, Muchardt C, et al. An injected bacterial effector targets chromatin access for transcription factor NF-κB to alter transcription of host genes involved in immune responses. Nature Immunol 2007;8:47–56; doi: https://doi.org/10.1038/ni1423

80. Netea MG, Joosten LA, Latz E, Mills KH, Natoli G, Stunnenberg HG, et al. Trained immunity: a program of innate immune memory in health and disease. Science 2016;352(6284):aaf1098; doi: https://doi.org/10.1126/science.aaf1098

81. Lu T, Das S, Howlader DR, Picking WD, Picking WL. Shigella vaccines: the continuing unmet challenge. Int J Mol Sci 2024;25:4329; doi: https://doi.org/10.3390/ijms25084329

82. Mancini F, Micoli F, Necchi F, Pizza M, Berlanda Scorza F, Rossi O. GMMA-Based Vaccines: the Known and The Unknown. Front Immunol 2021;12:715393; doi: https://doi.org/10.3389/fimmu.2021.715393

83. Fanucchi S, Domínguez-Andrés J, Joosten LAB, Netea MG, Mhlanga MM. The Intersection of Epigenetics and Metabolism in Trained Immunity. Immunity 2021;54:32–43; doi: https://doi.org/10.1016/j.immuni.2020.10.011

Article Metrics
2 Views 0 Downloads 2 Total

Year

Month

Related Search

By author names

Similar Articles